Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innogenetics has granted GlaxoSmithKline Biologicals a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological human papillomavirus vaccine studies.
Subscribe to our email newsletter
GlaxoSmithKline (GSK) has licensed Innogenetics’s SPF10 primer technology in order to continue its current and future clinical and epidemiological studies in the context of further development of some of their prophylactic vaccines directed against human papillomavirus (HPV). Innogenetics will receive royalties for each individual test performed during the studies.
In addition, Innogenetics recently obtained the CE-mark for its Inno-LiPA HPV Genotyping Extra assay, a product allowing the genotyping of 28 different HPV genotypes, of which 18 are high-risk genotypes. This product is based on the use of the short polymerase chain reaction fragment (SPF)10 primer set, which allows the detection of multiple HPV genotypes with high sensitivity and specificity.
Christiaan Wilde, CEO of Innogenetics, said: “This agreement demonstrates the significant value of our intellectual property in the field of HPV. Furthermore, it highlights the potential of our current HPV genotyping technology in serving the needs of clinical labs and pharmaceutical companies.”